| Jul 19 |
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
|
| Jul 19 |
Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday
|
| Jul 17 |
Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
|
| Jun 20 |
19 Analysts Have This To Say About Sage Therapeutics
|
| Jun 12 |
SAGE's Huntington's Disease Study Meets Primary Endpoint
|
| Jun 11 |
Sage spikes after mid-stage win for Huntington's disease therapy
|
| Jun 11 |
Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
|
| Jun 5 |
Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
|
| May 30 |
Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
|
| May 29 |
Baird predicts steady growth for SAGE Therapeutics at $15 target
|
